JS207 Combination Therapy in Triple-negative Breast Cancer
ConditionTriple-negative Breast Cancer
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-75
SponsorShanghai Junshi Bioscience Co., Ltd.
About this trial
This is an open-label, multi-center, phase II clinical study to preliminarily evaluate the efficacy and safety of JS207 combined with 9MW2821 or albumin paclitaxel as first-line therapy in patients with recurrent or metastatic TNBC.
Eligibility criteria
Qualifiers
Male or female age 18 - 75 years old；
Voluntary participation in clinical study；
Histologically confirmed unresectable, locally advanced or metastatic triple-negative breast cancer(absence of HER2, ER, and PR expression);
No prior systemic antitumor therapy for locally advanced or Metastatic TNBC；
Disqualifiers
Untreated or active central nervous system (CNS) metastases；
Uncontrolled pleural effusion, pericardial effusion or ascites；
Tumor encasement of important vessels or significant necrosis and cavitation that may cause a risk of hemorrhage；
History of significant bleeding tendency or severe coagulation disorder；
Trial design
Treatments tested in this trial
- JS207 in combination with 9MW2821
- JS207 in combination with Albumin paclitaxel
Treatment groups
80 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov